Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis

Authors

Ryan Geffin
Shazia Raheem
Lavannya M Pandit
Andrew S Hunter
Michael W Holliday
Aditya V Rao
Maulin K Shah

Publication Date

1-1-2023

Journal

Journal of Investigative Medicine High Impact Case Reports

DOI

10.1177/23247096231200386

PMID

37732474

PMCID

PMC10515550

PubMedCentral® Posted Date

9-21-2023

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes

Keywords

Adult, Humans, Child, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Peritoneal Dialysis, nephrology, dialysis, peritoneal dialysis, COVID-19, SARS-CoV-2, remdesivir

Abstract

End-stage kidney disease (ESKD) has been shown to be correlated with an increased risk of COVID-19 infection and mortality. Remdesivir is an effective non-EUA U.S. Food and Drug Administration (FDA)-approved antiviral agent for the treatment of COVID-19 in hospitalized adult and pediatric patients, though a lack of data has prevented its use in patients with severe kidney disease including dialysis patients. Some observational studies report the use of remdesivir in hemodialysis patients, but there are no reports of patients treated with remdesivir on peritoneal dialysis. Dialysis modalities may affect drug pharmacokinetics, and safety and efficiency of remdesivir in peritoneal dialysis is unknown. We report the first case, to our knowledge, of using remdesivir in a patient treated with peritoneal dialysis with no significant adverse events. This case illustrates the potential for remdesivir to be considered in peritoneal dialysis patients with severe COVID infection. Proper risk analysis and careful monitoring should be done, given the unpredictable clearance of the drug.